^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Gastric Cancer
    Drug:elzovantinib (TPX-0022) (Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

    Excerpt:
    ...Histological or cytological confirmation of advanced/metastatic MET exon 14 skipping mutation (METΔex14) NSCLC, MET amplified NSCLC, or MET amplified gastric cancers as determined by FISH, qPCR or NGS by local liquid biopsy or tissue, solid tumors with MET fusions or oncogenic MET mutations or MET amplified other than GI/NSCLC....
    Trial ID:
    SHIELD-1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR-NCI-EORTC 2020
    Title:

    First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET

    Published date:
    10/11/2020
    Excerpt:
    MET alterations included amplification (N=9), Δex14 (n=7) and fusion (n=2)....TPX-0022 is a novel MET/SRC/CSF1R inhibitor. TPX-0022 was generally well-tolerated. Responses were observed in Δex14 NSCLC and MET amplified GC and CRC.